Back for a fourth year, innovatED will be featured in the Exhibit Hall Sunday through Tuesday. Presented by Janssen Cardiovascular, Pharmaceutical Companies of Johnson and Johnson, Mallinckrodt Pharmaceuticals, and Samsung NeuroLogica, this space features a self-guided tour of the latest emergency medicine technology and services, presented by dozens of companies.
Explore This IssueACEP16 Sunday Daily News
Somebody has to take charge, lead, come up with something new. Where is that person? You can find many of the trailblazers in the Exhibit Hall at innovatED. This space features products and services vetted by a team of emergency physicians that are showcased working together in a true-to-life environment. Engage in dialogue with the companies and experience the current thinking, departmental design solutions, cutting-edge products and services, and best practices driving change in the ED. This experience is particularly valuable for those looking to rebuild their emergency medicine services or bring their facility up to speed on new technologies.
Who’s driving change in EM? The people and companies listed here.
Janssen Cardiovascular, Pharmaceutical Companies of Johnson and Johnson
As a member of the Janssen Pharmaceutical Companies, Janssen Pharmaceuticals, Inc. is dedicated to addressing and resolving the major unmet medical needs of our time. Driven by our commitment to patients, health care professionals, and caregivers, we strive to develop sustainable and integrated health care solutions by working in partnership with all stakeholders on the basis of trust and transparency. Our daily work is guided by meeting goals of excellence in quality, innovation, safety, and efficacy in order to advance patient care. For more information on Janssen Pharmaceuticals, Inc., visit us at www.janssenpharmaceuticalsinc.com
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation, and manufacturing capabilities. The company’s Specialty Brands segment includes branded medicines. Its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. The Global Medical Imaging segment includes contrast media and nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
“Mallinckrodt Pharmaceuticals is a global specialty biopharmaceutical company committed to providing products that help practitioners manage the pain of patients in the acute care hospital setting. We take pride in supporting ACEP and share a dedication to providing patients the highest quality and safest care.” —Jodi Devlin, Vice President and General Manager, Hospital Acute Care, Mallinckrodt Pharmaceuticals